Integrative Complementary Alternative Medicine Research and Development Center, Khon Kaen University, Khon Kaen 40002, Thailand.
Department of Physiology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
Oxid Med Cell Longev. 2017;2017:5290161. doi: 10.1155/2017/5290161. Epub 2017 Aug 20.
The novel protectant against diabetic cataract and diabetic retinopathy is currently required due to the increased prevalence and therapeutic limitation. Based on the advantage of polyphenol on diabetic eye complications, we hypothesized that the combined extract of mango seed Vietnamese coriander (MPO), a polyphenol-rich substance, should possess anticataractogenesis and antiretinopathy in streptozotocin- (STZ-) diabetic rats. MPO at doses of 2, 10, and 50 mg/kg·BW were orally given to STZ-diabetic rats for 10 weeks. Lens opacity was evaluated every week throughout a study period whereas the evaluation of cataract severity and histological changes of both rat lens epithelium and retina together with the biochemical assays of oxidative stress status, aldose reductase, p38MAPK, ERK1/2, and VEGF were performed at the end of experiment. Our data showed that MPO improved cataract and retinopathy in STZ-diabetic rats. The improved oxidative stress status and the decreased p38MAPK, ERK1/2, and VEGF were also observed. Therefore, anticataractogenesis and antiretinopathy of MPO might occur partly via the decreased oxidative stress status and the suppression of aldose reductase, p38MAPK, ERK1/2, and VEGF. This study points out that MPO is the potential candidate protectant against diabetic cataract and diabetic retinopathy. However, the exploration for possible active ingredient (S) still requires further researches.
由于糖尿病性白内障和糖尿病性视网膜病变的患病率增加和治疗限制，目前需要一种新型的保护剂。鉴于多酚对糖尿病眼部并发症的优势，我们假设富含多酚的芒果籽芫荽（MPO）的复合提取物应该具有抗白内障形成和抗糖尿病性视网膜病变的作用。MPO 以 2、10 和 50mg/kg·BW 的剂量口服给予链脲佐菌素（STZ）-糖尿病大鼠，持续 10 周。在整个研究期间，每周评估晶状体混浊度，而在实验结束时，评估白内障严重程度和大鼠晶状体上皮和视网膜的组织学变化，并进行氧化应激状态、醛糖还原酶、p38MAPK、ERK1/2 和 VEGF 的生化测定。我们的数据表明，MPO 改善了 STZ 糖尿病大鼠的白内障和视网膜病变。还观察到氧化应激状态的改善和 p38MAPK、ERK1/2 和 VEGF 的减少。因此，MPO 的抗白内障形成和抗糖尿病性视网膜病变作用部分可能是通过降低氧化应激状态和抑制醛糖还原酶、p38MAPK、ERK1/2 和 VEGF 来实现的。这项研究指出，MPO 是防治糖尿病性白内障和糖尿病性视网膜病变的潜在候选保护剂。然而，对可能的有效成分（S）的探索仍需要进一步的研究。
